1791842
Last Update Posted: 2019-03-21
Recruiting has ended
All Genders accepted | 18 Years + |
19 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
TOCILIZUMAB IN FIBROUS DYSPLASIA OF BONE
Bone pain due to fibrous dysplasia of bone is usually treated with bisphosphonates. A small proportion of patients fail to respond adequately. Mutated bone cells produce large amounts of Interleukin-6 (IL-6), with increased bone resorption as a result. Inhibition of IL-6 may be of interest to reduce bone resorption and therefore bone pain. TOCIDYS is a placebo-controlled randomized cross-over trial to test the hypothesis that tocilizumab can reduce bone resorption in those patients with fibrous dysplasia who have already received bisphosphonates.
Eligibility
Relevant conditions:
Fibrous Dysplasia of Bone
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov